Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2016; 22(47): 10432-10439
Published online Dec 21, 2016. doi: 10.3748/wjg.v22.i47.10432
Published online Dec 21, 2016. doi: 10.3748/wjg.v22.i47.10432
Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
Marta Maia Bosca-Watts, Inflammatory Bowel Disease Unit, Digestive Disease Department, University of Valencia, University Clinic Hospital of Valencia, 46010 Valencia, Spain
Xavier Cortes, Digestive Disease Department, Hospital of Sagunto, 46010 Valencia, Spain
Marisa Iborra, Gastroenterology Department and CIBEREHD, Hospital Universitari i Politecnic La Fe, 46026 València, Spain
Jose Maria Huguet, Digestive Disease Department, General Hospital of Valencia, 46014 Valencia, Spain
Laura Sempere, Digestive Disease Department, General Hospital of Alicante, 03010 Alacant, Spain
Gloria Garcia, Digestive Disease Department, San Juan University Hospital of Alicante, 46010 Valencia, Spain
Rafa Gil, Digestive Disease Department, Arnau Hospital of Valencia, 46015 València, Spain
MariFe Garcia, Digestive Disease Department, General University Hospital of Elche, 03203 Alicante, Spain
Marga Muñoz, Pedro Almela, Digestive Disease Department, General Hospital of Castellon, 12004 Castellón de la Plana, Spain
Nuria Maroto, Inflammatory Bowel Disease Unit, Digestive Disease Department, Hospital of Manises, 46940 Manises, Spain
Jose Maria Paredes, Digestive Disease Department, Peset University Hospital of Valencia, 46017 València, Spain
Author contributions: All authors included patients for the study, contributed to the review of the medical literature and wrote and/or reviewed the article; all listed authors approved the final version of the manuscript.
Institutional review board statement: This study was approved by the Institutional Review Board.
Conflict-of-interest statement: None of the authors has any conflict of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Marta Maia Bosca-Watts, PhD, MD, Inflammatory Bowel Disease Unit, Digestive Disease Department, University of Valencia, University Clinic Hospital of Valencia, Avda. Blasco Ibañez 17, 46010 Valencia, Spain. inflamatoriahcuv@gmail.com
Telephone: +34-96-1973500
Received: August 9, 2016
Peer-review started: August 11, 2016
First decision: September 5, 2016
Revised: September 25, 2016
Accepted: October 31, 2016
Article in press: October 31, 2016
Published online: December 21, 2016
Processing time: 131 Days and 21 Hours
Peer-review started: August 11, 2016
First decision: September 5, 2016
Revised: September 25, 2016
Accepted: October 31, 2016
Article in press: October 31, 2016
Published online: December 21, 2016
Processing time: 131 Days and 21 Hours
Core Tip
Core tip: Golimumab is a fully humanized anti-tumor necrosis factor-alpha monoclonal antibody, which has recently been accepted in clinical practice. Pivotal studies have demonstrated the drug’s benefits, but real-life studies are still scarce. This observational, prospective and multi-center study in moderate-severe ulcerative colitis patients, confirmed golimumab’s short-term (14 wk) effectiveness. A high percentage of patients had responded and were off steroids at the end of follow-up. No severe adverse events were observed. Intensification (reducing the drug administration interval or increasing the dosage) may be useful in many slow-to-respond cases.